Ocugen, Inc. Announces Submission of Investigational New Drug Application with U.S. FDA to Initiate a Phase 1 Clinical Trial Evaluating OCU200 for the Treatment of Diabetic Macular Edema Read more
Lantern Pharma and TTC Oncology Establish AI Collaboration to Expand the Clinical Development of Drug Candidate TTC-352 Read more
Keymed and Lepu Biopharma have announced a global exclusive licensing agreement with AstraZeneca for CMG901 Read more
Xspray Pharma and EVERSANA team up for U.S. launch and commercialization of Dasynoc (XS004), a promising therapy for CML and ALL Read more
Sage Therapeutics’ SAGE-718 granted Orphan Drug Designation by European Medicines Agency for Huntington’s Disease treatment Read more
Moderna and Life Edit Therapeutics Form Strategic Partnership to Advance In Vivo Gene Editing Therapies Read more
A strategic partnership for GMP plasmid DNA manufacturing for an mRNA COVID-19 vaccine candidate has been announced by GenScript ProBio and RVAC Medicines Read more
The EU has approved the tablet formulation of Calquence for patients suffering from chronic lymphocytic leukaemia Read more
Eterna Therapeutics and Lineage Cell Therapeutics Partner to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications Read more
Beckley Psytech’s BPL-003, a synthetic formulation of 5-MeO-DMT (Mebufotenin), granted FDA Investigational New Drug (IND) approval for Phase IIb clinical trial Read more